Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Clinical Trials

9 recruiting

Frequently Asked Questions

Common questions about Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal (Jiangsu) Pharmaceutical Co., Ltd.66 enrolled15 locationsNCT07154264
Recruiting
Phase 2

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Seema Bhat61 enrolled1 locationNCT06757647
Recruiting
Phase 2

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal Pharmaceuticals155 enrolled17 locationsNCT06539182
Recruiting
Phase 3

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal (Jiangsu) Pharmaceutical Co., Ltd.250 enrolled2 locationsNCT07139873
Recruiting
Not Applicable

The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients

Indolent Non-hodgkin LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Mayo Clinic70 enrolled2 locationsNCT05876923
Recruiting
Not Applicable

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

Chronic Lymphocytic LeukemiaAtrial FibrillationSupraventricular Arrhythmia+2 more
Northwell Health50 enrolled1 locationNCT05643235
Recruiting
Phase 2

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaCLL/SLL+1 more
Zulfa Omer34 enrolled1 locationNCT06978088
Recruiting
Phase 1

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Diffuse Large B-Cell Lymphoma+16 more
City of Hope Medical Center37 enrolled1 locationNCT06859008
Recruiting
Phase 1

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Ono Pharmaceutical Co. Ltd108 enrolled14 locationsNCT06547528
Recruiting
Phase 1Phase 2

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731